Typhoid in Africa and vaccine deployment

Gordon Dougan

doi:10.1016/s2214-109x(17)30045-1

Abstract

Typhoid in Africa and vaccine deployment

Highlights

Typhoid, one of the classic infectious diseases afflicting humanity, is still a relatively common illness in many lower-income and middle-income countries (LMIC).[1]
Multidrug resistance has been increasingly reported as a characteristic of S Typhi isolated in the past decade and from different parts of the globe.[4]
Multidrug resistant S Typhi respond more slowly to antibiotic treatment,[7] and such strains might be stimulating an increased use of antibiotics in the community, where antibiotics are freely available without prescription

Summary

Introduction

One of the classic infectious diseases afflicting humanity, is still a relatively common illness in many lower-income and middle-income countries (LMIC).[1]. These are not always present in LMIC settings and the incidence of typhoid in many regions, Africa, remains relatively undefined. A new generation of typhoid vaccines, based on conjugate technology and the Vi capsular antigen of S Typhi, are being developed and have been licenced in some countries.[8]

Results

Conclusion